Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions

Nan H. Jeong, Nak Woo Lee, Mi Kyung Woo, Hong J. Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of the study was to investigate the seroprevalence to HPV type 16 in Korean women with precancerous and cancerous lesions of the uterine cervix. The cases were 173 Korean women of whom 130 had high-grade cervical intraepithelial neoplasias (CIN), 43 cervical carcinomas and the control group was 106 women showing normal cervical cytology. Serologic assays were performed using HPV-16 VLPs as antigen in an ELISA. Specific antibodies against HPV-16 VLP were detected in 59.2% (77/130) of the patients with high-grade CIN, in 67.4% (29/43) of the patients with cervical cancer and in 20.8% (22/106) of control subjects. No difference of serologic response was found between high-grade CIN and cancer. HPV-16 seropositivity showed the significant association with patients' age and preoperative HPV DNA infection. Recurrence of high-grade CIN was not affected by the VLP-16 seropositivity. Recurrence of carcinoma showed the borderline association with HPV-16 seropositivity (P=0.06). The association between the cancer recurrence and seropositivity was not found in the logistic regression analysis. Two patients dying of cancer during the follow-up period were both seronegative (P=0.01). In conclusion, serologic testing for HPV-16 VLP antibody provides a disease indicator of cervical lesions and potential prognostic parameter of cervical carcinoma.

Original languageEnglish
Pages (from-to)383-389
Number of pages7
JournalArchives of Pharmacal Research
Volume32
Issue number3
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Papillomaviridae
Human papillomavirus 16
Viruses
Virion
Cervical Intraepithelial Neoplasia
Association reactions
Cytology
Antibodies
Carcinoma
Recurrence
Regression analysis
Logistics
Assays
Antigens
Neoplasms
DNA
Seroepidemiologic Studies
Testing
Cervix Uteri
Uterine Cervical Neoplasms

Keywords

  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • Enzyme-linked immunosorbent assay
  • Human papillomavirus
  • Serology
  • Virus-like particles

ASJC Scopus subject areas

  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery

Cite this

Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions. / Jeong, Nan H.; Lee, Nak Woo; Woo, Mi Kyung; Kim, Hong J.

In: Archives of Pharmacal Research, Vol. 32, No. 3, 01.03.2009, p. 383-389.

Research output: Contribution to journalArticle

@article{276e6751834547d489d62c42380ae5aa,
title = "Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions",
abstract = "The aim of the study was to investigate the seroprevalence to HPV type 16 in Korean women with precancerous and cancerous lesions of the uterine cervix. The cases were 173 Korean women of whom 130 had high-grade cervical intraepithelial neoplasias (CIN), 43 cervical carcinomas and the control group was 106 women showing normal cervical cytology. Serologic assays were performed using HPV-16 VLPs as antigen in an ELISA. Specific antibodies against HPV-16 VLP were detected in 59.2{\%} (77/130) of the patients with high-grade CIN, in 67.4{\%} (29/43) of the patients with cervical cancer and in 20.8{\%} (22/106) of control subjects. No difference of serologic response was found between high-grade CIN and cancer. HPV-16 seropositivity showed the significant association with patients' age and preoperative HPV DNA infection. Recurrence of high-grade CIN was not affected by the VLP-16 seropositivity. Recurrence of carcinoma showed the borderline association with HPV-16 seropositivity (P=0.06). The association between the cancer recurrence and seropositivity was not found in the logistic regression analysis. Two patients dying of cancer during the follow-up period were both seronegative (P=0.01). In conclusion, serologic testing for HPV-16 VLP antibody provides a disease indicator of cervical lesions and potential prognostic parameter of cervical carcinoma.",
keywords = "Cervical cancer, Cervical intraepithelial neoplasia, Enzyme-linked immunosorbent assay, Human papillomavirus, Serology, Virus-like particles",
author = "Jeong, {Nan H.} and Lee, {Nak Woo} and Woo, {Mi Kyung} and Kim, {Hong J.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1007/s12272-009-1311-1",
language = "English",
volume = "32",
pages = "383--389",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "3",

}

TY - JOUR

T1 - Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions

AU - Jeong, Nan H.

AU - Lee, Nak Woo

AU - Woo, Mi Kyung

AU - Kim, Hong J.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - The aim of the study was to investigate the seroprevalence to HPV type 16 in Korean women with precancerous and cancerous lesions of the uterine cervix. The cases were 173 Korean women of whom 130 had high-grade cervical intraepithelial neoplasias (CIN), 43 cervical carcinomas and the control group was 106 women showing normal cervical cytology. Serologic assays were performed using HPV-16 VLPs as antigen in an ELISA. Specific antibodies against HPV-16 VLP were detected in 59.2% (77/130) of the patients with high-grade CIN, in 67.4% (29/43) of the patients with cervical cancer and in 20.8% (22/106) of control subjects. No difference of serologic response was found between high-grade CIN and cancer. HPV-16 seropositivity showed the significant association with patients' age and preoperative HPV DNA infection. Recurrence of high-grade CIN was not affected by the VLP-16 seropositivity. Recurrence of carcinoma showed the borderline association with HPV-16 seropositivity (P=0.06). The association between the cancer recurrence and seropositivity was not found in the logistic regression analysis. Two patients dying of cancer during the follow-up period were both seronegative (P=0.01). In conclusion, serologic testing for HPV-16 VLP antibody provides a disease indicator of cervical lesions and potential prognostic parameter of cervical carcinoma.

AB - The aim of the study was to investigate the seroprevalence to HPV type 16 in Korean women with precancerous and cancerous lesions of the uterine cervix. The cases were 173 Korean women of whom 130 had high-grade cervical intraepithelial neoplasias (CIN), 43 cervical carcinomas and the control group was 106 women showing normal cervical cytology. Serologic assays were performed using HPV-16 VLPs as antigen in an ELISA. Specific antibodies against HPV-16 VLP were detected in 59.2% (77/130) of the patients with high-grade CIN, in 67.4% (29/43) of the patients with cervical cancer and in 20.8% (22/106) of control subjects. No difference of serologic response was found between high-grade CIN and cancer. HPV-16 seropositivity showed the significant association with patients' age and preoperative HPV DNA infection. Recurrence of high-grade CIN was not affected by the VLP-16 seropositivity. Recurrence of carcinoma showed the borderline association with HPV-16 seropositivity (P=0.06). The association between the cancer recurrence and seropositivity was not found in the logistic regression analysis. Two patients dying of cancer during the follow-up period were both seronegative (P=0.01). In conclusion, serologic testing for HPV-16 VLP antibody provides a disease indicator of cervical lesions and potential prognostic parameter of cervical carcinoma.

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - Enzyme-linked immunosorbent assay

KW - Human papillomavirus

KW - Serology

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=65449177715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449177715&partnerID=8YFLogxK

U2 - 10.1007/s12272-009-1311-1

DO - 10.1007/s12272-009-1311-1

M3 - Article

C2 - 19387582

AN - SCOPUS:65449177715

VL - 32

SP - 383

EP - 389

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 3

ER -